Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
294 Results for "
dermatitis
" in MedChemExpress (MCE) Product Catalog:
Products (294)
294 Results for "dermatitis" in MCE Product Catalog:
Synonyms: BOD FL alkyne
Category:
Target:
Cat. No.: HY-170977
Research Areas:
JAK1/STAT3-IN-1 (compound 4f) is an anti-AD (atopic dermatitis) agent by inhibiting JAK1/STAT3 signaling pathway. JAK1/STAT3-IN-1 inhibits NO generation with an IC50 of 2.17 μM. JAK1/STAT3-IN-1 improves the skin condition of AD-like mice, reduces inflammatory infiltration, inhibits the expressions of p-JAK1/JAK1 and p-STAT3/STAT3, and mitigates the excessive immune response on Calcipotriol (HY-10001) (MC903)-induced AD-like mice .
Cat. No.: HY-175022
CAS No.: 2432992-21-5
Research Areas:
PROTAC IRAK4 degrader-13 (Degrader 1) is a selective IRAK4 PROTAC degrader with DC50s of 0.86 and 1.1 nM for monocytes and lymphocytes in PBMCs, respectively. PROTAC IRAK4 degrader-13 significantly induces TIR signal activation, and inhibits the expression of circulating proinflammatory cytokines in Imiquimod (HY-B0180) induced psoriasis mice model. PROTAC IRAK4 degrader-13 can be used for TLR- and IL-1R-driven driven neutrophilic inflammation diseases like hidradenitis suppurativa (HS) and atopic dermatitis (AD) research . Pink: IRAK4 ligand; Blue: E3 ligase ligand; Black: linker
Cat. No.: HY-189433
Research Areas:
Keap1-Nrf2 PPI-IN-2 is a Keap1-Nrf2 PPI inhibitor with an EC50 of 14.2 μM. Keap1-Nrf2 PPI-IN-2 covalently binds to Keap1 cysteine residues through its electrophilic itaconate moiety, disrupts the Keap1-Nrf2 protein-protein interaction, releases Nrf2, and promotes its nuclear translocation and antioxidant gene expression, thereby reducing ROS and inhibiting IL-13 production . Keap1-Nrf2 PPI-IN-2 can be used for research on atopic dermatitis .
Cat. No.: HY-76711R
CAS No.: 16590-41-3
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Naltrexone (Standard) is the analytical standard of Naltrexone (HY-76711). This product is intended for research and analytical applications. Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.
Cat. No.: HY-76711S
CAS No.: 2070009-29-7
Cat. No.: HY-P10580
CAS No.: 1359657-45-6
Research Areas:
Cat. No.: HY-P10580A
Research Areas:
Cat. No.: HY-P990281
Target:
Research Areas:
Cat. No.: HY-P990735
CAS No.: 2765066-99-5
Synonyms: UCB-1381
Target:
Research Areas:
Cat. No.: HY-184965
CAS No.: 2020058-38-0
Target:
Research Areas:
S-Y048 is an orally active OXE receptor-selective antagonist with picomolar-level IC50 values (0.02-30 nM) and pIC50 values of (10.47-10.81) against human receptors. S-Y048 selectively blocks the 5-oxo-ETE signaling pathway, inhibits actin polymerization, calcium mobilization, leukocyte migration, as well as allergen-induced leukocyte infiltration in skin and lung tissues, and reduces mucin-producing bronchial epithelial cells. S-Y048 undergoes benzyl, N-methyl and α-hydroxylation reactions to form metabolites in monkeys. S-Y048 can be used in research related to asthma, allergic asthma, allergic eosinophilic diseases, atopic dermatitis and allergic rhinitis .
Cat. No.: HY-19205B
CAS No.: 205654-37-1
Research Areas:
(2S,5S)-CMI-392 is the absolute configuration of CMI-392 (HY-19205A). CMI-392 is an orally active dual 5-lipoxygenase inhibitor and platelet-activating factor receptor (PAFR) antagonist, with an IC50 of 10 nM for human PAF receptor and an IC50 of 100 nM for rat 5-lipoxygenase. CMI-392 blocks PAF receptor binding, inhibits leukotriene synthesis, attenuates PAF-induced hemoconcentration, and suppresses arachidonic acid- and TPA-induced ear swelling in mice. CMI-392 reduces inflammatory cell infiltration, decreases MPO levels, alleviates ocular inflammation, and improves dextran sulfate sodium-induced colitis. CMI-392 can be used in the research of inflammatory and immune-related diseases such as colitis and atopic dermatitis .
Cat. No.: HY-N10093
CAS No.: 69618-96-8
Synonyms: Chamaejasmin
Cat. No.: HY-NP229
Cat. No.: HY-167597S
C18:0-d7 GD1b Ceramide (d18:1/18:0-d7) is the deuterated-labeled C18:0 GD1b Ceramide (d18:1/18:0), synthetic (HY-167597). C18:0 GD1b Ceramide (d18:1/18:0), synthetic is a synthetic ganglioside. C18:0 GD1b Ceramide (d18:1/18:0), synthetic is a Ganglioside GD1b derivative and a high-purity research standard. C18:0 GD1b Ceramide (d18:1/18:0), synthetic can be used for research on atopic dermatitis and Alzheimer's disease .
Target:
Research Areas:
FITC (Fluorescein Isothiocyanate) (solution) , is one of the green fluorescein derivatives widely used in biology. FITC has the characteristics of high absorptivity and excellent fluorescence quantum yield. The isothiocyanate group of FITC can be combined with amino, sulfhydryl, imidazole, tyrosyl, carbonyl and other groups on the protein, so as to achieve protein labeling including antibodies and lectins. In addition to its use as a protein marker, FITC can also be used as a fluorescent protein tracer to rapidly identify pathogens by labeling antibodies, or for microsequencing of proteins and peptides (HPLC). The maximum excitation wavelength of FITC is 494 nm. Once excited, it fluoresces yellow-green at a maximum emission wavelength of 520 nm. In addition, FITC is also a hapten that can induce contact hypersensitivity (CHS) and induce an atopic dermatitis model .
Solvent and concentration: DMSO: 20 mM
The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.
Solvent and concentration: DMSO: 20 mM
The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.
Cat. No.: HY-N3963
CAS No.: 82425-45-4
Synonyms: (+)-Gomisin M2
Target:
Cat. No.: HY-W017982
CAS No.: 55965-84-9
Synonyms: CMI/MI
Research Areas:
CMIT/MIT (14.5% in water) (CMI/MI) is a mixture of CMIT and MIT, and is also a preservative and skin sensitizer. CMIT/MIT (14.5% in water) increases the levels of phosphorylated ERK1/2, p38, JNK1/2, p53, p21 and Bax, decreases the level of Bcl-2, and activates the Nrf-2/HO-1 signaling pathway. CMIT/MIT (14.5% in water) increases LDH release and lipid peroxidation levels, impairs antioxidant defense capacity, promotes pro-inflammatory cytokine release, induces apoptosis, triggers cell cycle arrest, exhibits neurotoxicity in neuroblastoma cells, and causes dysregulation of Th2/Th17 immune responses. CMIT/MIT (14.5% in water) can be used in studies related to allergy, atopic dermatitis and lung injury .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
